Dosing and Administration of XOLAIR (omalizumab)

Overview

• XOLAIR is an injectable prescription medicine used for chronic spontaneous urticaria (CSU) in individuals aged 12 and older not controlled by H1 antihistamines.
• It is administered subcutaneously.

Self-Injection

Two Methods of Self-Injection

• Autoinjector
• Prefilled Syringe

Getting Started

• Initial training is required with a healthcare provider before self-injection.
• Children 12 and older may self-inject under adult supervision.
• Instructions for Use are available in the XOLAIR carton.

Important Safety Information

Severe Allergic Reaction

• Anaphylaxis, a severe allergic reaction, may occur after any dose.
• Symptoms include wheezing, shortness of breath, dizziness, and swelling.

Contraindications

• Do not use if allergic to omalizumab or its ingredients.

Precautions

• Inform your healthcare provider if you have allergies, a history of anaphylaxis, parasitic infections, cancer, pregnancy, or are breastfeeding.

Administration Guidelines

• XOLAIR is administered every 4 weeks.
• Initial doses are supervised by a healthcare provider.
• Do not stop other hive medications unless directed by a healthcare provider.

Side Effects

Serious Side Effects

• Cancer: Observed in some patients.
• Fever, muscle aches, rash within 1 to 5 days post-injection.
• Parasitic infections in some at-risk individuals.
• Heart and circulation problems reported.

Common Side Effects

• Nausea, headaches, nasal swelling, cough, joint pain, upper respiratory infection.

Support and Resources

• Support For You Program: Offers 1-on-1 sessions and financial assistance options.
• Patient Resources: FAQs, downloadable resources, and the XOLAIR Journey Guide.

Legal and Contact Information

• Side effects can be reported to the FDA or Genentech.
• Full prescribing information and medication guides are available online.